title: Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal.
abstract: OBJECTIVE
  To evaluate the efficacy of 0.9% bromfenac (Xibrom™) or a celecoxib-impregnated intraocular lens (celecoxib-IOL) compared with 1% prednisolone acetate (PA) in controlling postoperative inflammation and posterior capsule opacification (PCO).
  
  
  METHODS
  Fifty-nine dogs undergoing cataract extraction by phacoemulsification.
  
  
  METHODS
  Bilateral patients received bromfenac or celecoxib-IOL plus PA in one eye, and PA in the contralateral eye. Unilateral patients received bromfenac or PA. Complete ophthalmic examination including tonometry, slit-lamp grading of flare and PCO, and digital image acquisition for masked PCO evaluation was performed within 24 h and 1, 4, 12, 24, and 56 weeks following surgery.
  
  
  RESULTS
  Celecoxib-IOL/PA-treated eyes had significantly less flare than PA-treated eyes, which had significantly less flare than bromfenac-treated eyes 24 h postoperatively. There was no significant difference in intraocular pressure (IOP) postoperatively, or at 1, 24, or 56 weeks. Celecoxib-IOL/PA-treated eyes had significantly lower IOP measurements than bromfenac and PA-treated eyes at 4 and 12 weeks. There was no significant difference in PCO level between groups using slit-lamp biomicroscopy at any time point. Masked evaluation of digital images revealed significantly less PCO in celecoxib-IOL/PA- vs. bromfenac-treated eyes at 4 weeks, and in bromfenac- vs. PA-treated eyes at 56 weeks.
  
  
  CONCLUSIONS
  Eyes receiving celecoxib-IOL/PA had better initial control of inflammation. Bromfenac was equally effective compared with PA in controlling inflammation. There was no association between COX-2 inhibitor administration and ocular hypertension. Celecoxib-IOL/PA-treated eyes showed better initial control of PCO (up to 12 weeks), while eyes receiving bromfenac had better long-term control of PCO (56 weeks).
authors.affiliation: Animal Eye Care, Chesapeake, VA, 23320, USA.
authors.forename: Heather L
authors.initials: HL
authors.lastname: Brookshire
authors.forename: Robert V
authors.initials: RV
authors.lastname: English
authors.forename: Bradley
authors.initials: B
authors.lastname: Nadelstein
authors.forename: Anne K
authors.initials: AK
authors.lastname: Weigt
authors.forename: Barrett W
authors.initials: BW
authors.lastname: Gift
authors.forename: Brian C
authors.initials: BC
authors.lastname: Gilger
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use*; D001969:Bromobenzenes / Q000627:therapeutic use*; D000068579:Celecoxib / Q000008:administration & dosage / Q000627:therapeutic use*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004283:Dog Diseases / Q000628:therapy*; D004285:Dogs; D007249:Inflammation / Q000517:prevention & control / Q000662:veterinary*; D007429:Intraocular Pressure; D007910:Lenses, Intraocular / Q000662:veterinary; D018918:Phacoemulsification / Q000009:adverse effects / Q000662:veterinary*; D011239:Prednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D001577:Benzophenones; D001969:Bromobenzenes; D052246:Cyclooxygenase 2 Inhibitors; C053083:bromfenac; C009935:prednisolone acetate; D011239:Prednisolone; D000068579:Celecoxib
keywords: Bromfenac; celecoxib; intraocular lens implant; phacoemulsification; posterior capsule opacification; prednisolone acetate